{{Rsnum
|rsid=13106616
|Chromosome=4
|position=34041798
|Orientation=plus
|GMAF=0.2461
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 2.8 | 19.3 | 78.0
| HCB | 7.5 | 39.1 | 53.4
| JPT | 7.3 | 39.1 | 53.6
| YRI | 25.2 | 43.4 | 31.5
| ASW | 8.8 | 36.8 | 54.4
| CHB | 7.5 | 39.1 | 53.4
| CHD | 9.3 | 35.5 | 55.1
| GIH | 6.1 | 25.3 | 68.7
| LWK | 23.4 | 51.4 | 25.2
| MEX | 3.6 | 35.7 | 60.7
| MKK | 12.9 | 52.3 | 34.8
| TSI | 2.0 | 18.2 | 79.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs13106616
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.15, combined P value= 4.89E-05. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470172
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs13106616
|overall_frequency_n=28
|overall_frequency_d=128
|overall_frequency=0.21875
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=26
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}